At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 105 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
BIA 9-1067 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
In Brief
A Phase 1 clinical trial evaluating BIA 9-1067 and Placebo for Parkinson Disease. Completed, enrolled 105 participants across 1 site.
Detailed Summary
To assess the pharmacokinetics of BIA 9-1067 in healthy Japanese subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedJan 2012
Primary CompletionNov 2012
TodayJul 2026
First PostedJan 30, 2012
Enrollment StartMay 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.4 years ago
Interventions
BIA 9-1067drug
5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
Placebodrug
once-daily